New Inspection Findings on Novo Nordisk's Diabetes Pill Raise Concerns

New Inspection Findings on Novo Nordisk's Diabetes Pill Raise Concerns

A recent Food and Drug Administration (FDA) inspection has revealed the presence of “objectionable” bacteria in several batches of semaglutide, a key diabetes pill manufactured by Novo Nordisk. Between February and June, seven batches were found to have unexpected forms of bacteria, including one known to cause meningitis. Although Novo Nordisk has responded to the FDA’s observations, the inspection findings could have significant implications f…